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I. INTRODUCTION 
Medicare1 is about to begin offering prescription drug 
benefits.2  Providing drug benefits through the Medicare program 
is a noted achievement that may help ease the financial pressures 
faced by millions of older Americans.  It is noteworthy that 
Medicare will include coverage for off-label use3 of some 
prescription drugs.4  Prescriptions for off-label use of drugs 
continue to climb,5 while concerns about the safety of off-label use 
 
       †     Cynthia A. Moyer is a 1990 graduate of Harvard Law School and a 
shareholder with the Minneapolis law firm of Fredrikson & Byron, P.A., where she 
practices in the business litigation group, focusing on health law and intellectual 
property.   
 1. Medicare is a social health insurance program that provides basic hospital 
coverage for Americans sixty-five years of age or older.  Social Security Act, 42 
U.S.C. § 1395(c) (2000).  It also provides coverage for some people under age 
sixty-five with disabilities and for people with end-stage renal disease.  Id. 
 2. On December 8, 2003, President George W. Bush signed into law the 
Medicare Prescription Drug, Improvement and Modernization Act of 2003, which 
amended Title XVIII of the Social Security Act.  See 42 U.S.C. § 1395w-101.  The 
prescription drug benefit program will become available to beneficiaries 
beginning in January 2006.  42 U.S.C. § 1395w-101(a)(2). 
 3. “Off-label use” refers to a use other than the FDA-approved uses.  See 
Kaspar J. Stoffelmayr, Comment, Products Liability and ‘Off-Label’ Uses of Prescription 
Drugs, 63 U. CHI. L. REV. 275, 276–82 (1996). 
 4. See Medicare Program; Medicare Prescription Drug Benefit, 69 Fed. Reg. 
46,632 (proposed Aug. 3, 2004) (describing the rules proposed by the Centers for 
Medicare & Medicaid Services (CMS) to implement the new Medicare 
Prescription Drug Benefit).  
 5. See Paul D. Rheingold & David B. Rheingold, Offense or Defense?  Managing 
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are also on the rise.6  Concerns regarding off-label use include fears 
about untested prescribing practices7 and patients agreeing to a 
suggested course of treatment, at least in part, because the risks are 
not known—by the physician or the patient.8  Concerns also exist 
regarding the pharmaceutical companies’ promotion of off-label 
use as a means to increase sales while side stepping the onerous 
FDA approval process.9  Such promotion encourages the 
prescription of drugs for uses that have not undergone rigorous 
study and may increase risk to patients. 
Who decides whether a drug can be used off-label and under 
what circumstances?  If a physician decides to prescribe a drug off-
label, what legal issues, if any, should the physician be aware of?  
 
the Off-Label Use Claim, 37 TRIAL 52, 52 (2001) (observing that there has been an 
increase in off-label claims by injured plaintiffs because off-label use of medical 
products is a growing practice); see also Veronica Henry, Off-Label Prescribing Legal 
Implications, 20 J. LEGAL MED. 365, 365 (1999) (“According to some estimates, 
almost half the United States population currently may be taking a medication 
prescribed for an unapproved reason.”). 
 6. See Alison Young & Chris Adams, “Off-label” Drugs Take Their Toll, KNIGHT 
RIDDER NEWSPAPERS, Nov. 2, 2003, at http://realcities.com/mld/krwashington/ 
news/special_packages/riskyrx/7146578.htm (last visited Jan. 21, 2005). 
 7. See James M. Beck & Elizabeth D. Azari, FDA, Off-Label Use, and Informed 
Consent:  Debunking Myths and Misconceptions, 53 FOOD & DRUG L.J. 71, 72 (1998).  
In discussing the fen/phen controversy of the late 1990s, the authors noted: 
[T]he popular media discovered that the commonly prescribed 
combination of fenfluramine and phentermine was an off-label use.  
Both drugs had been approved separately for labeling and marketing for 
short-term use in weight reduction, but they often had been prescribed 
together for not only short-term, but long-term weight-loss treatment.  
Millions of people used one or more of the drugs. 
Id. at 71. 
 8. Young & Adams, supra note 6. “A six month Knight Ridder investigation 
has found that patients nationwide are being injured and killed as doctors 
routinely prescribe drugs in ways the FDA never certified as safe and effective.”  Id.   
 9. Stoffelmayr, supra note 3, at 277.  Manufacturers have a strong and 
obvious incentive to encourage off-label use since such uses increase overall sales.  
Id. at 279–80.  The author explained: 
[D]espite the FDA restrictions, manufacturers have been very successful 
at promoting off-label uses.  Among the most common methods are 
funding research into off-label drug uses, sponsoring continuing 
education programs and symposia in which ostensibly independent 
researchers discuss off-label uses, distributing reprints of journal articles 
on off-label uses, and purchasing special journal supplements that 
feature articles about off-label uses. 
Id. at 280; see also Rheingold & Rheingold, supra note 5, at 53 (arguing “[o]ff-label 
use is a fiscal boon to manufacturers. . . .  Fen-phen is perhaps the best example of 
this.  Sales of two drugs that had virtually no market when prescribed under their 
FDA approval suddenly skyrocketed when doctors began to prescribe them 
together and for a long period.”). 
2
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With the increased practice of prescribing drugs for off-label use, 
coupled with a somewhat dated and incomplete medical 
negligence standard in Minnesota, the intersection of the off-label 
use doctrine with Minnesota’s medical negligence standard is ripe 
for review. 
This article examines the off-label use doctrine and the 
medical negligence standard under Minnesota law.  First, the 
article examines what the phrase “off-label use” means.10  Next, the 
article explores the cases that have arisen in Minnesota which 
address medical malpractice claims arising, at least in part, because 
of off-label uses.11  Finally, the article concludes with the author’s 
observations about whether off-label use should be a cause for 
concern.12  In part, the author considers whether increased off-
label use presents new legal issues for physicians, patients, and 
attorneys.13 
II. WHAT IS OFF-LABEL USE? 
In 1962, Congress amended the Food Drug and Cosmetic Act14 
(the Act) to give the FDA the power to assess the safety and 
effectiveness of all drugs before they could be sold in the United 
States.15  The Drug Amendments of 1962 constitute a 
comprehensive regulatory scheme that addresses the 
manufacturing and marketing of drugs for human use.16  Under 
the Act, before a drug can be marketed it must receive FDA 
approval.17  The FDA will not grant approval unless a drug is shown 
to be safe and effective.18  Moreover, prior to marketing, the FDA 
reviews the package literature.19  The package literature, commonly 
 
 10. See infra Part II.  This article addresses off-label use only in the context of 
prescription drugs.  The phrase is also used in connection with medical devices, 
which is a use not addressed in this article. 
 11. See infra Part III. 
 12. See infra Part IV. 
 13. See id. 
 14. 21 U.S.C. §§ 301–99 (2000). 
 15. See recitation of legislative history in 21 U.S.C. § 301 (adding sections 
358–60, and amending sections 321, 331, 332, 348, 351, 353, 355, 357, 372, 374, 
376, and 381 (collectively referred to as the “Drug Amendments of 1962”)). 
 16. Id. 
 17. 21 U.S.C. § 355(a) (2000).  For a description of the FDA approval process 
for new drugs, see David A. Kessler, The Regulation of Investigational Drugs, 320 NEW 
ENG. J. MED. 281, 281–83 (1989). 
 18. 21 U.S.C. § 355(d). 
 19. See 21 C.F.R. §§ 201.56–.57, 201.100 (2004). 
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referred to as the “package insert,” may only refer to the approved 
uses for the drug.20 
The complex and detailed regulatory scheme used by the FDA 
to assess whether, and under what circumstances, a drug can be 
marketed creates the public perception that drugs with FDA 
approval are tested and safe for all circumstances in which they are 
used.  Yet the FDA has always tried to steer clear of interfering with 
the practice of medicine.  Thus, the FDA openly acknowledges that 
“the FD&C Act does not limit the manner in which a physician may 
use an approved drug.”21  The FDA does not exercise any oversight 
over the practice of medicine.22 
The presence of the complex and lengthy regulatory process 
required to bring a new drug to market, oversight by the FDA, and 
the FDA’s hands-off approach to the practice of medicine gives rise 
to a fact that is little known to the public at large.  Namely, once a 
drug receives FDA approval, physicians may prescribe that drug for 
any purpose, including, but not limited to, the FDA approved use.23 
Prescribing a drug for a use other than the FDA approved use 
is commonly referred to as “off-label”24 or “unlabeled”25 use.  Off-
label use of an FDA approved product is defined as a “specific use 
for which that product has not been approved.”26  Off-label use can 
take several forms, including prescribing an approved drug to treat 
a disease or condition that is not indicated on the manufacturer’s 
label, treating the indicated disease but varying the approved 
dosage, or prescribing the drug to a patient population other than 
the intended patient population.27 
Off-label use is extremely common, with one study suggesting 
that most hospital patients receive at least one drug off-label,28 and 
 
 20. The package insert must contain certain information intended to ensure 
safe and effective use of the drug, including information relating to the following 
topics: description; clinical pharmacology; indications and usage; 
contraindications; warnings; precautions; adverse reactions; drug abuse and 
dependence; over-dosage; dosage and administration; how supplied; and date of 
most recent revision to the labeling.  21 C.F.R. § 201.56. 
 21. 12 FOOD & DRUG BULL. 3, 5 (1982). 
 22. Id. 
 23. Id. 
 24. William L. Christopher, Off-Label Drug Prescription: Filling the Regulatory 
Vacuum, 48 FOOD & DRUG L.J. 247, 248 (1993). 
 25. 12 FOOD & DRUG BULL., supra note 21, at 5. 
 26. In re Kessler, 100 F.3d 1015, 1015 n.1 (D.C. Cir. 1997). 
 27. Christopher, supra note 24, at 248. 
 28. Scott Esposito, Off-Label Prescribing of Drugs Calls FDA Role Into Question, 
PITTSBURGH TRIB.-REV., Nov. 25, 2000 (citing Alex Tabarrok, Assessing the FDA via 
4
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that the off-label use of some popular medications constitutes more 
than half of all sales.29  For some drugs, off-label uses account for 
ninety percent of all prescriptions sold for the drug.30  In addition 
to being extremely common, the practice of off-label prescribing 
appears to be increasing.31  At least one study found that off-label 
prescriptions nearly doubled from 1998 to 2003.32  The rise in off-
label prescription drug use will most likely continue, particularly in 
light of the change in Medicare law.33 
Is increased off-label use a cause for concern?  Not necessarily.  
Whether off-label use implies increased risk depends on the 
circumstances.  As the FDA explained, “the term ‘unapproved uses’ 
is, to some extent, misleading.  It includes a variety of situations 
ranging from unstudied to thoroughly investigated drug uses.”34  
For those situations where off-label use has been thoroughly 
investigated, it is accepted practice, and may even constitute 
malpractice if an off-label use is not offered to patients.35  In 
addition, off-label drug use plays a significant role in advances in 
drug therapy and medical care.36  In other cases, even if an off-label 
use is not dangerous, such use may not be ethically or politically 
appropriate.37 
Because an FDA-approved drug can be prescribed for any 
purpose, this article examines the constraints on physician off-label 
prescribing practices under the Minnesota malpractice doctrine; 
specifically, as it has evolved in cases concerning prescription 
drugs. 
 
the Anomaly of Off-Label Drug Prescribing, THE INDEP. REV., Summer 2000), at 
http://www.independent.org/printer.asp?page=%2Fnewsroom%2Farticle%2Easp
?ID=179 (last visited Jan. 21, 2005). 
 29. Knight Ridder Washington Bureau, Unapproved Drug Uses Study, Nov. 2003 
(showing off-label prescriptions for the following drugs constituted more than half 
of all prescriptions:  Seroquel, Risperdal, Neurontin, Topamax, Biaxin XL, 
Trazodone HCI, Bextra, and Avelox), at http://161.188.204.190/krdigital/drug. 
 30. Chris Adams & Alison Young, FDA Oversight of ‘Off-Label’ Drug Use Wanes, 
KNIGHT RIDDER NEWSPAPERS, Nov. 4, 2003, at http://www.realcities.com/mld/ 
krwashington/news/special_packages/riskyrx/7152542.htm. 
 31. Id. 
 32. Id. 
 33. See supra note 4 and accompanying text. 
 34. 12 FOOD & DRUG BULL. 4, 5 (April 1982). 
 35. Stoffelmayr, supra note 3, at 278. 
 36. Henry, supra note 5, at 383 (noting that “[t]he regulatory process has not 
been able to keep pace with innovation” and “[i]n many cases, off-label 
prescribing is the standard of care.”). 
 37. Christopher, supra note 24, at 249. 
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III. THE STATE OF THE LAW IN MINNESOTA 
In a medical malpractice action, the plaintiff must offer expert 
testimony to establish the standard of care and the defendant’s 
departure from it.38  If the case concerns allegations of improper 
use of prescription drugs, is the fact that a physician deviated from 
the package insert relevant to establishing the standard of care?  
The answer under Minnesota law as it currently stands is 
“possibly.”39 
The Minnesota Civil Jury Instruction Guides includes a 
proposed jury instruction for claims of negligence by medical 
professionals resulting from departures from drug manufacturers’ 
instructions.40  The proposed jury instruction sets forth the 
standard for negligence, stating: 
A (doctor) (dentist) is negligent if: 
1.  The drug manufacturer gave clear and explicit  
recommendations (and) (or) instructions for use of the 
drug, and; 
2.  The (doctor) (dentist) did not follow these 
recommendations (and) (or) instructions. 
The (doctor) (dentist) is negligent unless a reasonable 
(doctor) (dentist) would not have followed these 
recommendations (and) (or) instructions under the 
circumstances.41 
Three cases form the basis for this proposed jury instruction and 
each case is discussed below.42 
In 1970, in Mulder v. Parke Davis & Co., the Minnesota 
Supreme Court announced its rule with regard to the 
circumstances under which off-label use constitutes medical 
negligence.43  The court initially described its rule as follows: 
“Where the dosage is prescribed by the manufacturer, testimony of 
the physician’s failure to adhere to its recommendation is sufficient 
evidence to require him to explain the reason for his deviation.  
 
 38. See Todd v. Eitel Hosp., 306 Minn. 254, 257, 237 N.W.2d 357, 359 (1975). 
 39. See infra Part IV. 
 40. See MINN. DIST. JUDGES ASS’N, MINN. PRACTICE SERIES, 4A JURY INSTRUCTION 
GUIDES—CIVIL, CIVJIG 80.16, (4th ed. 1999). 
 41. Id. 
 42. The three cases are: Reinhardt v. Colton, 337 N.W.2d 88 (Minn. 1983); 
Lhotka v. Larson, 307 Minn. 121, 238 N.W.2d 870 (1976); Mulder v. Parke Davis & 
Co., 288 Minn. 332, 181 N.W.2d 882 (1970). 
 43. 288 Minn. 332, 181 N.W.2d 882. 
6
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This is particularly true where the manufacturer’s warning puts the 
doctor on notice of potentially lethal effects.”44 
Two months later, in response to a petition for rehearing by 
the Minnesota State Medical Association as amicus curiae, the court 
expanded its rule: 
Where a drug manufacturer recommends to the medical 
profession (1) the conditions under which its drug should 
be prescribed; (2) the disorders it is designed to relieve; 
(3) the precautionary measures which should be 
observed; and (4) warns of the dangers that are inherent 
in its use, a doctor’s deviation from such 
recommendations is prima facie evidence of negligence if 
there is competent medical testimony that his patient’s 
injury or death resulted from the doctor’s failure to 
adhere to the recommendations.45 
The court also made clear that when such circumstances exist 
“it is incumbent on the doctor to disclose his reasons for departing 
from the procedures recommended by the manufacturer.”46  The 
court acknowledged that it would “ordinarily be a jury question” 
whether the physician justified or excused his deviation from the 
manufacturer guidance.47 
The Minnesota Supreme Court next addressed the issue in 
1976.48  The court in Lhotka v. Larson considered whether a so-
called Mulder instruction was warranted where the plaintiff alleged 
that the defendant physician “knowingly deviated from the 
manufacturers’ instructions and recommendations on the use of 
drugs which were administered in this case.”49  By the slimmest of 
margins the court disagreed and, in the process, narrowed the 
Mulder holding.50  The court concluded that a Mulder instruction 
was not appropriate because the evidence did not establish a clear 
deviation from the manufacturers’ instructions,51 and the drug 
 
 44. Id. at 339, 181 N.W.2d at 887 (citing Magee v. Wyeth Labs. Inc., 29 Cal. 
Rptr. 322, 328 (1963)). 
 45. Id at 339–40, 181 N.W.2d at 887. 
 46. Id. at 340, 181 N.W.2d at 887. 
 47. Id. 
 48. See Lhotka v. Larson, 307 Minn. 121, 238 N.W.2d 870 (1976). 
 49. Id. at 125, 238 N.W.2d at 873. 
 50. Chief Justice Sheran wrote the majority opinion, which three other 
justices joined.  Id. at 121, 238 N.W.2d at 870.  Four justices, Chanak, joined by 
Kelly, Todd, and Scott, dissented, and one justice, Otis took no part in the 
consideration or decision of the case.  Id. at 133, 238 N.W.2d at 878. 
 51. Id. at 127, 238 N.W.2d at 874 (stating “[w]e hold on these facts there was 
7
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manufacturers’ recommendations were not sufficiently clear and 
explicit to support the requested instruction.52  The court also 
noted that “[u]nderlying Mulder is the self-evident premise that 
deviation from a manufacturer’s recommendations constitutes 
prima facie evidence of negligence only when the conduct 
complained of deviates from standards which are clear and 
explicit.”53 
As the Lhotka dissent makes clear, however, the majority’s 
holding rests on a thin reed.54  At issue in the case were the drugs 
given to a woman in premature labor.55  It was undisputed that the 
manufacturer’s insert for one of the drugs explicitly stated that 
“‘fetal immaturity constitutes a relative contraindication’ for 
administration . . . by injection.”56  The manufacturer’s insert with 
regard to oral administration (which is how the drug was 
administered to the plaintiff) contained no explicit 
contraindication.57  The dissent noted that the chemical 
composition, whether administered orally or by injection, was the 
same and, thus, the effect of the drug was essentially the same.58 
The dissent thus took the position that the jury should have 
been given a Mulder instruction, contingent upon a prior jury 
finding that the manufacturer’s recommendations were sufficiently 
clear to put a reasonably prudent physician on notice that oral 
administration was also contraindicated.59  The majority, however, 
concluded that the manufacturer’s recommendations were not 
clear as to oral administration and, therefore, a Mulder instruction 
was not appropriate.60 
In 1983, the Minnesota Supreme Court further refined the 
circumstances in which a so-called Mulder instruction might be 
 
no basis in the manufacturers’ instructions for a finding that the Doctors Larson 
failed to observe clear and explicit recommendations with respect to [the 
medications at issue].”). 
 52. Id. at 125, 238 N.W.2d at 873–74. 
 53. Id. at 128 n.14, 238 N.W.2d at 875 n.14 (emphasis added). 
 54. See id. at 131–33, 238 N.W.2d at 877–78. 
 55. See id. at 123, 238 N.W.2d at 872 (noting that physician prescribed the 
oral administration of three grains of Seconal, a brand of sodium secobarbital 
used as a sedative to ease apprehension). 
 56. Id. at 131, 238 N.W.2d at 877 (quoting from the plaintiffs’ Exhibit K). 
 57. Id. 
 58. Id. at 132, 238 N.W.2d at 877.  The only difference in terms of effects was 
that “the drug would metabolize more slowly when administered orally.”  Id. 
 59. Id. 
 60. Id. at 126, 238 N.W.2d at 874. 
8
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warranted in the medical malpractice case Reinhardt v. Colton.61  In 
Reinhardt, the court considered whether the trial court properly 
directed a verdict for the defendants in connection with the 
plaintiff’s claim of negligent treatment.62  In considering that issue, 
the Minnesota Supreme Court addressed two issues concerning 
Mulder. 
First, the court observed that a Mulder instruction is 
appropriate only “‘if there is competent medical testimony that 
[the] patient’s injury or death resulted from the doctor’s failure to 
adhere to the recommendations.’”63  Thus, in Reinhardt, although 
the plaintiff introduced evidence that the physician did not 
conduct a direct platelet count as recommended in the package 
insert, but rather only estimated blood platelets, the plaintiff failed 
to introduce evidence that the physician’s failure to take a direct 
platelet count was the direct cause of the plaintiff’s injuries.64 
Second, the court in Reinhardt questioned, but did not resolve, 
the issue of whether the type of off-label use was relevant to the 
analysis of whether a Mulder instruction is appropriate.65  The 
Reinhardt court observed that in Mulder it  
described the type of “package insert” which can serve as a 
standard of care in this context as one which 
recommends: “(1) the conditions under which its drug 
should be prescribed; (2) the disorders it is designed to 
relieve; (3) the precautionary measures which should be 
observed; and [which] (4) warns of the dangers which are 
inherent in its use.”66 
 The court then noted that unlike the off-label use in Mulder, 
 
 61. 337 N.W.2d 88 (Minn. 1983). 
 62. Id. at 92–93. 
 63. Id. at 95 (quoting Mulder v. Parke Davis & Co., 288 Minn. 332, 340, 181 
N.W.2d 882, 877 (1970)). 
 64. Id. 
 65. Id. at 95 n.4.  The court explained: 
The Food and Drug Administration did not approve the use of [the drug 
at issue] for rheumatoid arthritis until late 1978, and the package inserts 
admitted as evidence at trial and applicable to the treatment period 
(February 1977 to August 1977) do not list rheumatoid arthritis as an 
approved indication.  An issue therefore arises regarding whether the 
package inserts introduced at trial can serve as a standard of care under 
the criteria established in Mulder.  However, . . . we need not address this 
issue. 
Id. 
 66. Id. (quoting Mulder, 288 Minn. at 339, 181 N.W.2d at 877). 
9
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the off-label use at issue in Reinhardt was not a change in the 
recommended dosage.67  Instead, the physician defendant in 
Reinhardt had prescribed a drug to treat an indication for which the 
drug was not approved.68  As a result, the package inserts that were 
used as evidence at trial made no mention of the plaintiff’s ailment 
(the second factor identified in Mulder), thus raising the question 
of whether the package inserts were relevant.69  The court 
acknowledged that its holding on the evidentiary issue concerning 
causation eliminated the need to substantively address this second 
issue and so did not affirmatively resolve it.70  The Reinhardt 
decision certainly leaves open the question of whether off-label use 
to treat a different ailment even comes under the scope of Mulder.71 
IV. CONCLUSION 
In light of the dramatic increase in off-label use, where are 
physicians and patients left with respect to off-label use?  Despite 
the fact that Minnesota case law addressing issues of medical 
negligence in the context of off-label use is somewhat well-
entrenched,72 should physicians be concerned about a possible 
increase in exposure for off-label use?  Should patients be worried?  
The answer to both physician and patient fears is “probably not.” 
Under Minnesota law as it currently stands, a physician is held 
to the standard of care outlined in the manufacturer’s insert only 
when the packaging insert is explicit, the physician clearly deviated 
from the manufacturer’s recommendations or instructions, and the 
physician’s deviation caused harm to the patient.73  It is an open 
question whether Mulder is applicable only in dosage cases or 
whether it would also apply in cases involving prescriptions for 
indications not addressed in the manufacturer’s insert, which is a 
common form of off-label use, or for use in patient populations 
other than those recommended by the manufacturer.  The 
suggestion in Reinhardt is that a Mulder instruction could be 
 
 67. Compare Reinhardt, 337 N.W.2d at 95 n.4, with Mulder, 288 Minn. at 335, 
181 N.W.2d at 885. 
 68. Reinhardt, 337 N.W.2d at 95 n.4. 
 69. Id. 
 70. Id. 
 71. Id. 
 72. The three cases controlling medical negligence in Minnesota in the 
context of off-label prescription drug use were decided in 1983, 1976, and 1970. 
 73. Reinhardt, 337 N.W.2d at 95. 
10
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inappropriate in cases involving off-label use for a different 
indication.74 
As a result, the pronouncement in Mulder, which has been 
rejected by some courts,75 has been tempered by the subsequent 
decisions into a rule that holds physicians to a reasonable 
standard.76  The remaining legal questions are (1) whether Mulder 
applies to situations where a physician prescribes a drug to a 
patient outside of the manufacturer-defined patient populations, 
and (2) whether Mulder applies to situations where a physician 
prescribes a drug to treat a condition not referenced in the 
package insert. 
The Minnesota Supreme Court has yet to decide a case that 
directly answers these questions.  Until the Minnesota Supreme 
Court hears a case directly on point, it is unclear where the law 
stands.  By voicing concerns about the evidentiary value of the 
package insert, the Reinhardt court hinted that it might resolve the 
question about off-label use for treatment of an indication not 
mentioned on the package insert by concluding that the insert 
does not establish a standard of care in this type of case.  The court 
has provided no similar suggestion for off-label use in populations 
other than the manufacturer-defined patient group.  Attorneys are 
likely to make arguments for and against extending Mulder in both 
types of off-label use cases. 
It is unclear whether Minnesota will encounter a significant 
legal change as a result of increased off-label use.  Nevertheless, 
until the Minnesota Supreme Court addresses the law, or the state 
legislature initiates a change, the areas of uncharted waters for 
physicians are instances of off-label use for treatment of an 
indication other than those listed on the package insert, and 
 
 74. Id. at 95 n.4. 
 75. See Ramon v. Farr, 770 P.2d 131, 135 (Utah 1989).  The Ramon court 
noted that there is a split among authorities.  Id. at 134 (stating “[w]e recognize 
that the courts appear to be split on whether the recommendations contained in a 
package insert are prima facie evidence of the standard of care.”).  The Ramon 
court expressly declined to follow Mulder, observing that only “a few other states” 
have followed Mulder, and the Minnesota courts “have since retreated somewhat 
from the Mulder standard.”  Id. (citing Lhotka v. Larson, 307 Minn. 121, 131–32, 
238 N.W.2d 870, 877 (1976)).  The Ramon court adopted a rule that a 
manufacturer’s recommendations are “some evidence that the finder of fact may 
consider along with expert testimony on the standard of care.”  Id. at 135 (citing 
Salgo v. Leland Stanford Jr. Univ. Bd. of Trs., 317 P.2d 170, 180 (Cal. Ct. App. 
1957)). 
 76. Reinhardt, 337 N.W.2d at 95. 
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prescriptions given to patients outside the manufacturer-defined 
patient populations.  Today, Minnesota medical negligence law, 
although well-established, remains incomplete. 
Should patients be concerned about the rise in the use of off-
label prescriptions coupled with a Mulder holding that has been 
softened over the years?  No.  Physicians’ actions are, and will likely 
continue to be, judged against a reasonable standard of care that 
serves to constrain physicians from straying beyond the bounds of 
reasonableness.  In addition, patients have and continue to use 
tools at their disposal (both malpractice actions and complaints to 
the Board of Medical Practice77) to constrain prescribing practices.  
Patients also have the right to know the risks involved in 
recommended courses of treatment78 and should exercise that right 
by asking questions about the medications they are being given. 
 
 
 77. See Kollmorgen v. State Bd. of Med. Exam’rs, 416 N.W.2d 485 (Minn. Ct. 
App. 1988) (upholding a disciplinary order of the State Board of Medical 
Examiners resulting from an over-prescription of medication that deviated from 
the manufacturer’s recommendation). 
 78. See MINN. STAT. § 144.651, subd. 9 (2004) (Patient’s Bill of Rights). 
“Patients and residents shall be given by their physicians complete and current 
information concerning their diagnosis, treatment, alternatives, risks, and 
prognosis as required by the physician’s legal duty to disclose.”  Id. 
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